E4orf1 Improves Lipid and Glucose Metabolism in Hepatocytes: A Template to Improve Steatosis & Hyperglycemia

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Dhurandhar, Emily J ^a   Krishnapuram, Rashmi ^a   Hegde, Vijay ^a   Dubuisson, Olga ^a   Tao, Rongya ^b   Dong, X Charlie ^b   Ye, Jianping ^a   Dhurandhar, Nikhil V ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CELL PROTEIN; CYCLIC AMP; DEXAMETHASONE; GLUCAGON; PALMITIC ACID; PROTEIN E4ORF1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DOWN REGULATION; FATTY ACID OXIDATION; FATTY LIVER; GENETIC TRANSFECTION; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HYPERGLYCEMIA; LIPID METABOLISM; LIPOGENESIS; LIPOPROTEIN SECRETION; LIVER METABOLISM; METABOLIC REGULATION; MOUSE; NONHUMAN; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ADENOVIRUS E4 PROTEINS; ADENOVIRUSES, HUMAN; ANIMALS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; GENETIC VECTORS; GLUCOSE; HEP G2 CELLS; HEPATOCYTES; HUMANS; HYPERGLYCEMIA; LIPID METABOLISM; MICE; TRANSFECTION;

EID: 84867878591     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047813     Document Type: Article

References (24)

1. Diraison F, Moulin P, Beylot M, (2003) Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab 29: 478-485.
2. Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, et al. (2007) The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A 104: 12587-12594.
3. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, et al. (2006) Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49: 755-765.
4. Zhang D, Liu ZX, Choi CS, Tian L, Kibbey R, et al. (2007) Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance. Proc Natl Acad Sci U S A 104: 17075-17080.
5. Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, et al. (2009) Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A 106: 15430-15435.
6. Fabbrini E, Sullivan S, Klein S, (2010) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51: 679-689.
7. Korenblat KM, Fabbrini E, Mohammed BS, Klein S, (2008) Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 134: 1369-1375.
8. Vega GL, Chandalia M, Szczepaniak LS, Grundy SM, (2007) Metabolic correlates of nonalcoholic fatty liver in women and men. Hepatology 46: 716-722.
9. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, et al. (2005) Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 48: 634-642.
10. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, et al. (2002) Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87: 3023-3028.
11. Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ, (2004) Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2: 262-265.
12. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, et al. (2002) NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35: 373-379.
13. Clark JM, (2006) Weight loss as a treatment for nonalcoholic fatty liver disease. J Clin Gastroenterol 40 (Suppl 1):: S39-43.
14. Lam B, Younossi ZM, (2010) Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol 3: 121-137.
15. Krishnapuram R, Dhurandhar EJ, Dubuisson O, Kirk-Ballard H, Bajpeyi S, et al. (2011) A Template to Improve Glycemic Control without Reducing Adiposity or Dietary Fat. Am J Physiol Endocrinol Metab 300: E779-789.
16. Rogers PM, Mashtalir N, Rathod MA, Dubuisson O, Wang Z, et al. (2008) Metabolically favorable remodeling of human adipose tissue by human adenovirus type 36. Diabetes 57: 2321-2331.
17. Wang ZQ, Cefalu WT, Zhang XH, Yu Y, Qin J, et al. (2008) Human adenovirus type 36 enhances glucose uptake in diabetic and nondiabetic human skeletal muscle cells independent of insulin signaling. Diabetes 57: 1805-1813.
18. Trovato GM, Martines GF, Garozzo A, Tonzuso A, Timpanaro R, et al. (2010) Ad36 adipogenic adenovirus in human non-alcoholic fatty liver disease. Liver Int 30: 184-190.
19. Krishnapuram R, Dhurandhar EJ, Dubuisson O, Kirk-Ballard H, Bajpeyi S, et al. (2011) Template to improve glycemic control without reducing adiposity or dietary fat. Am J Physiol Endocrinol Metab 300: E779-789.
20. Dhurandhar EJ, Dubuisson O, Mashtalir N, Krishnapuram R, Hegde V, et al. (2011) E4orf1: A Novel Ligand that Improves Glucose Disposal in Cell Culture. PLoS ONE 6(8): e23394.
21. Erion DM, Ignatova ID, Yonemitsu S, Nagai Y, Chatterjee P, et al. (2009) Prevention of hepatic steatosis and hepatic insulin resistance by knockdown of cAMP response element-binding protein. Cell Metab 10: 499-506.
22. Yellaturu CR, Deng X, Cagen LM, Wilcox HG, Mansbach CM, 2nd, et al (2009) Insulin enhances post-translational processing of nascent SREBP-1c by promoting its phosphorylation and association with COPII vesicles. The Journal of biological chemistry 284: 7518-7532.
23. Tal M, Wu YJ, Leiser M, Surana M, Lodish H, et al. (1992) [Val12] HRAS downregulates GLUT2 in beta cells of transgenic mice without affecting glucose homeostasis. Proc Natl Acad Sci U S A 89: 5744-5748.
24. Samuel VT, Liu ZX, Wang A, Beddow SA, Geisler JG, et al. (2007) Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest 117: 739-745.